Lanterne Dx
Jon Bishop is the Founder/CEO at Lanterne Dx, where Jon implemented strong hiring and training techniques to promote team cohesiveness and streamline overall workflow. Jon represented the organization at industry conferences and events. In the past, Jon was also the Founder/CEO at HTL Clinical (now rebranded to Lanterne Dx) and HistoTox Labs. Jon facilitated regular leadership meetings to discuss progress on strategic goals, identify opportunities for improvement, and address challenges proactively. Jon also identified and pursued business development opportunities to grow the organization and increase revenue. Jon earned a BS in Biology from Radford University.
This person is not in any teams
Lanterne Dx
Lanterne Dx is a CAP-accredited and CLIA-certified full-service histopathology contract research organization (CRO) offering medically relevant non-clinical and clinical services to the pharmaceutical, biotech, and academic communities. Established in 2019, LDX’s 4500 sf laboratory is a state-of-the-art facility equipped to meet your end-to-end research needs. Comprised of PhD scientists, DVM and MD pathologists, image analysts, and certified histotechnicians, the LDX team provides expertise and guidance in developing individualized biomarker strategies for clients. Lanterne Dx’s capabilities include qualitative and quantitative IHC, IF, ISH, and microscopic applications. We deliver pre- and post-intervention analysis of clinically derived materials for diagnostics and characterization of anti-tumor efficacy endpoints. As a valuable complement to the IHC services, LDX also offers the latest imaging technology with high-throughput brightfield and IF whole-slide scanners, image analysis software, and secure cloud-based image hosting.